Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 12 of 1358 for:    Area Under Curve AND tablet

Bioequivalence Study of Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Under Fasting Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01645449
Recruitment Status : Completed
First Posted : July 20, 2012
Last Update Posted : July 20, 2012
Sponsor:
Information provided by (Responsible Party):
Dr. Reddy's Laboratories Limited

Brief Summary:
The purpose of this study is to compare and evaluate the single-dose oral bioavailability and to monitor the safety of subjects.

Condition or disease Intervention/treatment Phase
Healthy Drug: Atorvastatin Calcium Tablets, 80 mg Phase 1

Detailed Description:
An open label, balanced, randomized, two-treatment, two-period, two-way crossover oral bioequivalence' study of Atorvastatin Calcium 80 mg Tablets of Dr. Reddy's and Lipitor 80 mg Tablets of Pfizer Ireland Pharmaceuticals in healthy adult, human subjects under fasting conditions.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 77 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-way Crossover Oral BE Study of Atorvastatin Ca 80 mg Tablets of Dr. Reddy's and Lipitor 80 mg Tablets of Pfizer in Healthy Adult, Human Subjects Under Fasting Conditions
Study Start Date : June 2010
Actual Primary Completion Date : August 2010
Actual Study Completion Date : August 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Calcium

Arm Intervention/treatment
Experimental: Atorvastatin Calcium Tablets, 80 mg
Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Laboratories Limited
Drug: Atorvastatin Calcium Tablets, 80 mg
Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
Other Name: Lipitor 80 mg Tablets

Active Comparator: Lipitor 80 mg Tablets
Lipitor 80 mg Tablets of Pfizer Ireland Pharmaceuticals
Drug: Atorvastatin Calcium Tablets, 80 mg
Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
Other Name: Lipitor 80 mg Tablets




Primary Outcome Measures :
  1. Area under curve (AUC) [ Time Frame: Pre-dose at 0.00 hour and post-dose at 0.167, 0.333, 0.50, 0.667, 0.833, 1.00, 1.25, 1.50, 1.75, 2.00, 2.25, 2.50, 2.75, 3.00, 3.50, 4.00,6.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00, 48.00 and 72.00 hours ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Male and female subjects aged 18 - 55 (including) years old.
  2. Subjects' weight within normal range according to normal values for Body Mass Index (1 8.0 to 30.0 kg/m2) with minimum of 50 kg weight.
  3. Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within clinically acceptable range.
  4. Subjects having normal 12-lead electrocardiogram (ECG).
  5. systolic blood pressure between 90 mmHg to 145 mmHg (age 18 to 45 years) or 90 mmHg to 160 mmHg (above 45 years). Diastolic blood pressure between 50 mrnHg to 90 rnmHg. Pulse rate between 45 bpm and 100 bpm.
  6. Subjects having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, and morphine).
  7. Subjects having negative alcohol breath test.
  8. Women who are of childbearing potential must be using acceptable methods of birth control for 4 weeks prior to, during and 4 weeks after the last dose of trial medication and should be informed of the potential risks associated with becoming pregnant while enrolled within a clinical research trial. Accepted forms of contraception are: i.e. implants, injectables, hormonal intrauterine device, combined oral contraceptives, sexual abstinence and vasectomised sexual partner throughout the trial. Female volunteers who are post-menopausal, hysterectomised or surgically sterile may be enrolled.
  9. Subjects willing to adhere to the protocol requirements and to provide written informed consent.

Exclusion Criteria:

The subjects were excluded from the study, if they met any of the following criteria:

  1. Hypersensitivity to the test, or reference drug, or all other used ingredients, or related class of drugs.
  2. History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological,neurological or psychiatric disease or disorder.
  3. Individual or farniliy case medical history of any myopathy.
  4. Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 1 month before first dosing in Period 1.
  5. Medical history of muscular toxic reactions during treatment with statins of fibrates.
  6. Use of any prescribed or OTC medication or herbal supplements within 14 days or within 5 times the half-life of the respective active substance (whatever is longer), before first dosing in Period 1 (excluding contraceptives on women).
  7. History or presence of significant alcoholism or drug abuse in the past one year. Alcoholism is defined as consumption of more than 50g of ethanol per day (12.5 cL glass of 10° [l0%]] wine = 12 g; 4 cL of aperitif, 42° [42 %] whiskey = 17 g; 25 cL glass of 3° [3%] beer = 7.5 g; 25 cL glass of 6° [6%] beer = 15 g.
  8. History or presence of significant smoking (more than 10 cigarettes/day).
  9. History or presence of asthma, urticaria or other significant allergic reactions.
  10. History or presence of significant gastric andlor duodenal ulceration.
  11. History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
  12. History or presence of cancer.
  13. Difficulty with donating blood.
  14. Difficulty in swallowing solids like tablets or capsules.
  15. Major illness during 3 months before first dosing in Period 1.
  16. Participation in a drug research study within the past 1 month before first dosing in Period 1.
  17. Donation of blood in the past 2 months before first dosing in Period 1.
  18. Consumption of grapefruit juice, xanthine-containing products or alcohol for within 48 hours prior to dosing.
  19. Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.
  20. History or presence of significant easy bruising or bleeding.
  21. History or presence of significant recent trauma.
  22. Pregnancy or breast-feeding (for female subjects).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01645449


Locations
Layout table for location information
Germany
Nuvisan Pharma Services GmbH & Co. KG
Neu-Ulm, Germany, 89231
Sponsors and Collaborators
Dr. Reddy's Laboratories Limited
Investigators
Layout table for investigator information
Principal Investigator: Dr. med. Margarete Muller Nuvisan Pharma Services GmbH & Co. KG

Layout table for additonal information
Responsible Party: Dr. Reddy's Laboratories Limited
ClinicalTrials.gov Identifier: NCT01645449     History of Changes
Other Study ID Numbers: 10-VIN-095
First Posted: July 20, 2012    Key Record Dates
Last Update Posted: July 20, 2012
Last Verified: July 2012

Keywords provided by Dr. Reddy's Laboratories Limited:
Bioequivalence
Atorvastatin calcium
crossover

Additional relevant MeSH terms:
Layout table for MeSH terms
Calcium
Calcium, Dietary
Atorvastatin
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Bone Density Conservation Agents
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors